ClinicalTrials.gg
CompletedNCT04362410DIRECTION-CKUpdated Nov 17, 2020

Tezepelumab Phase 1 PK Study in Healthy Chinese Subjects

A Phase 1 interventional study of Experimental: Tezepelumab and Placebo in Healthy Subjects, sponsored by AstraZeneca. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-17.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2020, 6 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a Phase 1, Single Centre, Double-blind, Randomized, Placebo-controlled Parallel-group Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Tezepelumab after Single-Dose Subcutaneous Administration in Healthy Chinese Subjects.

Read the detailed description

This is a Phase 1, single centre, randomized, double-blind, placebo-controlled, single dose, parallel group study in healthy Chinese male or female subjects. 48 healthy subjects will be randomly assigned to one of the three treatment cohorts (i.e. 1:1:1 to Low dose, Medium dose and High dose) to receive a single dose of tezepelumab or placebo in a 3:1 ratio. Each subject will only participate in one cohort. Dose level is unblinded and treatment (tezepelumab or placebo) will be double-blinded within each treatment cohort. Following a screening period of a maximum of 28 days, subjects will stay at the study facility for two nights starting from the day before dosing (Day -1) to Day 2. Subjects will receive a single dose of tezepelumab or placebo subcutaneously on Day 1 and safety monitoring and serial collection of blood samples for PK evaluation will be followed throughout the study period. The follow up period after the dosing will be 112 days.

02

Conditions studied

  • Healthy Subjects

Keywords

  • Pharmacokinetics
  • Safety
  • Tolerability
  • Immunogenicity
  • Tezepelumab
  • Healthy Chinese Subjects
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female healthy Chinese subjects
  • Age 18 to 45
  • Body weight ≥ 40 kg
  • (BMI) between 19-24 kg/m2

Exclusion criteria

Exclusion Criteria:

  • History or evidence of a disorder
  • History of cancer
  • Smokers of > 5 cigarettes/day
  • Receipt of any marketed or biologic within 4 months or 5 half-lives/non-biologic agent within 30 days or 5 half-lives prior to randomization
  • History of chronic alcohol or drug abuse
  • , C or
  • Pregnant or breastfeeding
  • History of anaphylaxis following any biologic therapy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Tezepelumab: Low dose

    Tezepelumab: Tezepelumab single dose subcutaneously injection.

    Biological: Experimental: Tezepelumab

  • Experimental
    Tezepelumab: Medium dose

    Tezepelumab: Tezepelumab single dose subcutaneously injection.

    Biological: Experimental: Tezepelumab

  • Experimental
    Tezepelumab: High dose

    Tezepelumab: Tezepelumab single dose subcutaneously injection.

    Biological: Experimental: Tezepelumab

  • Placebo comparator
    Placebo

    Placebo single dose subcutaneously injection.

    Other: Placebo

Interventions

  • Tezepelumab single dose subcutaneously injection.

    Also known as: Tezepelumab

  • OtherPlacebo

    Placebo single dose subcutaneously injection.

06

What researchers measure

Primary outcomes

  1. AUC0-inf (Area under the serum concentration versus time curve from time zero to Infinity)

    To investigate the pharmacokinetics of single subcutaneous dose of tezepelumab in healthy Chinese subjects

    Time frame: Blood samples will be collected from Day 1 (3 hour prior to administration of IP) and on Day 2, Day 4, Day 6, Day 8, Day 10, Day 12, Day 15, Day 22, Day 29, Day 43, Day 57, Day 85 and Day 113.

  2. AUC0-t (Area under the serum concentration versus time curve from time zero to the last quantifiable concentration)

    To investigate the pharmacokinetics of single subcutaneous dose of tezepelumab in healthy Chinese subjects

    Time frame: Blood samples will be collected from Day 1 (3 hour prior to administration of IP) and on Day 2, Day 4, Day 6, Day 8, Day 10, Day 12, Day 15, Day 22, Day 29, Day 43, Day 57, Day 85 and Day 113.

  3. Cmax (Maximum serum concentration)

    To investigate the pharmacokinetics of single subcutaneous dose of tezepelumab in healthy Chinese subjects

    Time frame: Blood samples will be collected from Day 1 (3 hour prior to administration of IP) and on Day 2, Day 4, Day 6, Day 8, Day 10, Day 12, Day 15, Day 22, Day 29, Day 43, Day 57, Day 85 and Day 113.

  4. tmax (time to Cmax)

    To investigate the pharmacokinetics of single subcutaneous dose of tezepelumab in healthy Chinese subjects

    Time frame: Blood samples will be collected from Day 1 (3 hour prior to administration of IP) and on Day 2, Day 4, Day 6, Day 8, Day 10, Day 12, Day 15, Day 22, Day 29, Day 43, Day 57, Day 85 and Day 113.

  5. t1/2 (terminal serum half-life)

    To investigate the pharmacokinetics of single subcutaneous dose of tezepelumab in healthy Chinese subjects

    Time frame: Blood samples will be collected from Day 1 (3 hour prior to administration of IP) and on Day 2, Day 4, Day 6, Day 8, Day 10, Day 12, Day 15, Day 22, Day 29, Day 43, Day 57, Day 85 and Day 113.

  6. CL/F (apparent serum clearance)

    To investigate the pharmacokinetics of single subcutaneous dose of tezepelumab in healthy Chinese subjects

    Time frame: Blood samples will be collected from Day 1 (3 hour prior to administration of IP) and on Day 2, Day 4, Day 6, Day 8, Day 10, Day 12, Day 15, Day 22, Day 29, Day 43, Day 57, Day 85 and Day 113.

  7. Vz/F (apparent volume of distribution)

    To investigate the pharmacokinetics of single subcutaneous dose of tezepelumab in healthy Chinese subjects

    Time frame: Blood samples will be collected from Day 1 (3 hour prior to administration of IP) and on Day 2, Day 4, Day 6, Day 8, Day 10, Day 12, Day 15, Day 22, Day 29, Day 43, Day 57, Day 85 and Day 113.

Secondary outcomes

  1. Immunogenicity anti-drug antibodies

    Incidence of anti-drug antibodies following single dose of tezepelumab

    Time frame: Blood samples will be collected on Day 1 (3 hour prior to administration of IP) and on Day 29, Day 113.

07

Study locations

1 site
  • Research Site
    Nanchang, 330006, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Oct 2020, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2020
First posted
Apr 24, 2020
StartActual
May 18, 2020
Primary completionActual
Oct 9, 2020
CompletionActual
Oct 9, 2020
Last update
Nov 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04362410
Lead sponsor
AstraZeneca
Collaborators
Amgen
Responsible party
Sponsor
First posted
Apr 24, 2020
Start date
May 18, 2020
Primary completion
Oct 9, 2020
Completion
Oct 9, 2020
Last update
Nov 17, 2020

Study contacts

Jinfang Hu, Master
principal investigator · The First Affiliated Hospital of Nanchang University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion